查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081454

腦腫瘤治療市場：2026-2032年全球市場預測（依適應症、藥物類別、給藥途徑、療法、藥物類型、最終用戶和分銷管道分類）

Brain Cancer Drugs Market by Indication, Drug Class, Route Of Administration, Treatment Modality, Drug Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腦腫瘤治療市場將成長至 40.3 億美元，複合年成長率為 8.05%。

主要市場統計數據
基準年 2025 23.4億美元
預計年份：2026年 25.2億美元
預測年份 2032 40.3億美元
複合年成長率 (%) 8.05%

腦腫瘤的治療正從傳統的細胞毒性輔助性治療模式轉向基於生物標記的腫瘤治療，後者結合了烷化劑、標靶治療、免疫腫瘤學、腫瘤治療電場、放射性藥物以及複雜的臨床試驗設計。雖然膠質母細胞瘤仍然是成人中最具原發性的原發性腦瘤，但對於兒童和低度膠質瘤，分子分層對於指導治療選擇的重要性日益凸顯。

商業性和臨床重點受多種因素影響，例如未滿足的醫療需求高、血腦障壁滲透性低、腫瘤異質性以及標準治療後的復發。監管里程碑事件凸顯了這一轉變：Temozolomide仍然是新診斷膠質母細胞瘤的核心治療藥物，腫瘤治療領域（TTF）已獲得FDA批准用於治療膠質母細胞瘤。此外，Dabrafenib和Trametinib等聯合治療標靶治療組合正在拓展BRAF V600E變異型膠質瘤的治療選擇，而硼拉西地尼將於2024年獲得FDA批准用於治療術後IDH變異型2級星狀細胞瘤或少突膠質細胞瘤。

腦腫瘤治療領域的變革性變化

分子診斷、適應性臨床試驗以及基於腫瘤組織學類型和生物學特徵設計的治療方案正在改變腦腫瘤的治療現狀。 2021年世界衛生組織中樞神經系統腫瘤分類再次強調了IDH突變、1p/19q共缺失、H3 K27突變、MGMT啟動子甲基化以及其他標記在診斷和治療方案製定中的重要性。

人工智慧的累積影響

人工智慧（AI）正在對腦腫瘤治療的各個領域產生協同效應，從藥物發現和診斷到臨床試驗設計和治療監測。 AI驅動的放射組學有助於從MRI影像中量化腫瘤體積、水腫、壞死、偽序列和治療反應。同時，數位病理模型與專家評審相結合，正在改善腫瘤分級和生物標記解讀。

關鍵區域洞察

北美憑藉其緊密的神經腫瘤學網路、FDA孤兒藥獎勵、美國國家癌症研究所（NCI）資助的研究以及積極採用分子檢測技術，在腦腫瘤治療領域處於領先地位。美國仍然是新藥上市初期最重要的市場，而加拿大則透過其公共資助的腫瘤醫療保健系統、學術臨床試驗中心和系統化的醫療技術評估流程做出貢獻。

關鍵群體特定見解

七國集團（G7）憑藉其先進的監管體系、完善的報銷機制、在神經腫瘤學領域的學術專長以及較高的臨床試驗參與率，仍保持著強大的影響力。歐盟支持跨境研究合作和集中監管審查，為創新性腦腫瘤療法建立了系統化的路徑，儘管各成員國的衛生技術評估結果存在差異。北約成員國通常受益於成熟的醫療保健體系、可互通的研究生態系統以及強大的腫瘤學學術網路，這些都為臨床試驗的開展和證據的生成提供了支持。

主要國家的概況

美國是腦腫瘤治療藥物商業化和研究最活躍的市場，這得益於FDA的快速核准程序、孤兒藥核准途徑、綜合癌症中心以及雄厚的生物技術資金支持。加拿大提供參與高品質臨床試驗的機會、國家運營的腫瘤機構以及結構化的公共保險報銷審核流程。墨西哥和巴西是拉丁美洲的重要准入市場，其中巴西擁有該地區最大的癌症患者群體，而墨西哥則利用接近性。

為行業領導者提供的實用建議

產業領導者應優先考慮基於生物標記的研發策略、中樞神經系統（CNS）中可靠的藥物動力學證據，以及針對腫瘤免疫抑制、抗藥性和復發問題的聯合治療設計。研發計畫應在臨床規劃早期階段納入MGMT、IDH、BRAF、H3 K27、EGFR突變、TERT、1p/19q共缺失和其他相關標誌物，以最佳化病患篩選、符合監管要求並提升支付方的信任度。

調查方法

本執行摘要資訊來源二手研究，所用資料均來自已驗證的公共資源，包括監管公告、同行評審的癌症文獻、臨床試驗註冊資訊、癌症分類標準、治療指南以及公開的機構研究結果。本檢驗重點在於數據支持的趨勢，例如已通過核准的療法、公認的生物標記、既定的治療標準、已證實的診斷趨勢以及區域可及性。

結論

隨著分子診斷、中樞神經系統（CNS）最佳化療法和人工智慧驅動的研發重塑治療路徑，腦腫瘤治療市場正邁入一個更精準和技術主導的階段。儘管膠質母細胞瘤和復發性疾病仍面臨挑戰，但近期標靶治療的批准以及主導生物標記的臨床試驗設計表明，臨床上正在取得顯著進展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：腦腫瘤治療市場：依適應症分類

  • 膠質母細胞瘤
  • 腦膜瘤
  • 轉移性腦瘤
  • 腦下垂體瘤

第8章：腦腫瘤治療市場：依藥物類別分類

  • 化療
    • 烷化劑
    • 抗代謝物
    • 植物生物鹼
  • 免疫療法
    • 癌症疫苗
    • CAR-T療法
    • 查核點抑制劑
  • 支持性護理
    • 止吐藥
    • 生長因子
  • 標靶治療
    • 單株抗體
    • 蛋白酪氨酸激酶抑制劑

第9章：腦腫瘤治療藥物市場：依給藥途徑分類

  • 鞘內給藥
  • 靜脈
  • 口服

第10章：腦腫瘤治療市場：依治療方法分類

  • 單藥治療
  • 聯合治療

第11章：腦腫瘤治療市場：依藥物類型分類

  • 品牌
  • 非專利的

第12章：腦腫瘤治療市場：依最終用戶分類

  • 診所
  • 家庭醫療保健
  • 醫院

第13章：腦腫瘤治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 腦腫瘤治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：腦腫瘤治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 腦腫瘤治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Arbor Pharmaceuticals, LLC
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Chimerix, Inc.
  • Day One Biopharmaceuticals, Inc.
  • DNAtrix, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Emcure Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Ipsen SA
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc.
  • Kazia Therapeutics Limited
  • Merck & Co., Inc.
  • Merck KGaA
  • NextSource Pharmaceuticals, LLC
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Servier Pharmaceuticals LLC
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-434CCDA05263

The Brain Cancer Drugs Market is projected to grow by USD 4.03 billion at a CAGR of 8.05% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.34 billion
Estimated Year [2026] USD 2.52 billion
Forecast Year [2032] USD 4.03 billion
CAGR (%) 8.05%

Brain cancer drugs are moving from a historically cytotoxic, surgery-adjuvant model toward biomarker-guided oncology that combines alkylating agents, targeted therapies, immuno-oncology, tumor treating fields, radiopharmaceutical concepts, and precision trial designs. Glioblastoma remains the most aggressive primary malignant brain tumor in adults, while pediatric and lower-grade gliomas increasingly require molecular stratification to guide therapy selection.

The commercial and clinical focus is being shaped by high unmet need, limited blood-brain barrier penetration, tumor heterogeneity, and recurrence after standard-of-care therapy. Verified regulatory milestones underscore the shift: temozolomide remains central in newly diagnosed glioblastoma, tumor treating fields are FDA-authorized for glioblastoma, targeted combinations such as dabrafenib plus trametinib have expanded options for BRAF V600E-mutant glioma, and vorasidenib received FDA approval in 2024 for IDH-mutant grade 2 astrocytoma or oligodendroglioma after surgery.

Transformative Shifts in the Brain Cancer Drug Landscape

The brain cancer drugs landscape is being transformed by molecular diagnostics, adaptive clinical trials, and therapies designed around tumor biology rather than histology alone. The 2021 WHO Classification of Tumors of the Central Nervous System reinforced the importance of IDH mutation, 1p/19q codeletion, H3 K27 alterations, MGMT promoter methylation, and other markers in diagnosis and treatment planning.

Drug developers are prioritizing blood-brain barrier optimization, central nervous system pharmacokinetics, and combination regimens that can overcome immune suppression in the tumor microenvironment. The market is also seeing renewed interest in peptide vaccines, oncolytic viruses, checkpoint combinations, antibody-drug conjugates, PARP inhibitors, IDH inhibitors, and radiotherapy-sensitizing approaches, supported by growing genomic testing adoption in major oncology centers.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across discovery, diagnosis, trial design, and treatment monitoring in brain cancer drugs. AI-enabled radiomics can help quantify tumor volume, edema, necrosis, pseudoprogression, and treatment response from MRI, while digital pathology models are improving tumor grading support and biomarker interpretation when paired with expert review.

In drug development, machine learning is being used to screen compounds for CNS penetration, predict resistance pathways, identify patient subgroups, and optimize adaptive trial enrollment. Its most immediate value lies in reducing development inefficiency: brain cancer trials often struggle with small eligible populations, rapid progression, and imaging complexity, and AI can improve site selection, eligibility matching, longitudinal response assessment, and real-world evidence generation.

Key Regional Insights

North America leads in brain cancer drug development because of dense neuro-oncology networks, FDA orphan drug incentives, National Cancer Institute-supported research, and strong adoption of molecular testing. The United States remains the anchor market for first launches, while Canada contributes through publicly funded oncology systems, academic trial sites, and structured health technology assessment processes.

Europe benefits from EMA pathways, multinational cooperative research, and strong neuro-oncology centers across Germany, France, Italy, Spain, and the United Kingdom, although reimbursement timing varies by country. Asia-Pacific is expanding quickly as China, Japan, South Korea, Australia, and India strengthen oncology trial infrastructure, genomic medicine adoption, and specialist cancer care. Latin America, led by Brazil and Mexico, is improving access through specialty oncology centers and expanding private-sector diagnostics, while the Middle East shows rising demand in tertiary hospitals and national cancer programs. Africa remains more access-constrained, with availability shaped by neurosurgery capacity, pathology infrastructure, radiotherapy access, specialist availability, and reimbursement coverage.

Key Group Insights

The G7 markets remain highly influential because they combine advanced regulatory systems, reimbursement capacity, academic neuro-oncology expertise, and high participation in pivotal trials. The European Union supports cross-border research collaboration and centralized regulatory review, creating a structured pathway for innovative brain cancer drugs, although health technology assessment outcomes differ by member state. NATO-aligned markets generally benefit from mature health systems, interoperable research ecosystems, and strong academic oncology networks that support trial execution and evidence generation.

BRICS markets are strategically important for future patient access and clinical trial diversification, especially China, India, and Brazil, where cancer diagnostics, oncology infrastructure, and local innovation capacity are expanding. ASEAN is gaining relevance through Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines as specialist oncology services, private hospital networks, and molecular testing access improve. GCC countries are investing in advanced cancer care, national oncology strategies, international hospital partnerships, and medical tourism, creating stronger demand for precision brain cancer therapies in tertiary care settings.

Key Country Insights

The United States is the most active commercialization and research market for brain cancer drugs, supported by FDA expedited programs, orphan drug pathways, comprehensive cancer centers, and strong biotechnology funding. Canada provides high-quality trial participation, provincial cancer agencies, and structured public reimbursement review. Mexico and Brazil are important Latin American access markets, with Brazil offering the region's largest oncology base and Mexico benefiting from proximity to North American clinical and regulatory ecosystems.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine specialist neuro-oncology care with national reimbursement processes, biomarker testing expansion, and established academic trial networks, while Russia presents a more complex access environment shaped by reimbursement, procurement, and geopolitical constraints. China is scaling domestic oncology innovation, regulatory reform, and brain tumor clinical trials; India has a large patient base and growing precision diagnostics in major metropolitan cancer centers; Japan and South Korea offer sophisticated regulatory systems, advanced imaging, and strong translational research; and Australia is a highly connected clinical trial market with internationally recognized cancer centers and robust neuro-oncology expertise.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-defined development strategies, robust CNS pharmacokinetic evidence, and combination designs that address tumor immune suppression, resistance, and recurrence. Development plans should incorporate MGMT, IDH, BRAF, H3 K27, EGFR alteration, TERT, 1p/19q codeletion, and other relevant markers early in clinical planning to improve patient selection, regulatory alignment, and payer confidence.

Commercial teams should prepare for evidence requirements beyond response rate, including progression-free survival, overall survival, neurocognitive outcomes, steroid-sparing benefit, seizure control, quality of life, and real-world durability. Partnerships with academic neuro-oncology centers, imaging AI vendors, diagnostic laboratories, contract research networks, and patient advocacy groups can accelerate enrollment, strengthen evidence generation, and improve market access readiness across advanced and emerging oncology systems.

Research Methodology

This executive summary is based on secondary research from verified public sources, including regulatory agency announcements, peer-reviewed oncology literature, clinical trial registries, cancer classification standards, treatment guidelines, and publicly available institutional research outputs. The analysis emphasizes data-backed developments such as approved therapies, recognized biomarkers, established standards of care, documented diagnostic trends, and regional access dynamics.

The methodology combines qualitative market assessment, therapeutic landscape review, regulatory tracking, regional access evaluation, and technology trend analysis. Findings were synthesized to support executive content while avoiding unsupported market sizing claims, speculative revenue estimates, market share statements, forecasting, or unverified clinical performance claims.

Conclusion

The brain cancer drugs market is entering a more precise, technology-enabled phase as molecular diagnostics, CNS-optimized therapies, and AI-supported development reshape the treatment pathway. Despite persistent challenges in glioblastoma and recurrent disease, recent targeted therapy approvals and biomarker-led trial designs show that clinically meaningful progress is accelerating.

Organizations that align discovery, clinical development, diagnostics, regulatory strategy, and market access will be best positioned to compete. The strongest opportunities will emerge where therapeutic innovation is paired with validated biomarkers, measurable patient outcomes, rigorous evidence generation, and equitable access across advanced and emerging oncology systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Brain Cancer Drugs Market, by Indication

  • 7.1. Glioblastoma Multiforme
  • 7.2. Meningioma
  • 7.3. Metastatic Brain Tumors
  • 7.4. Pituitary Tumors

8. Brain Cancer Drugs Market, by Drug Class

  • 8.1. Chemotherapy
    • 8.1.1. Alkylating Agents
    • 8.1.2. Antimetabolites
    • 8.1.3. Plant Alkaloids
  • 8.2. Immunotherapy
    • 8.2.1. Cancer Vaccines
    • 8.2.2. CAR-T Therapy
    • 8.2.3. Checkpoint Inhibitors
  • 8.3. Supportive Therapy
    • 8.3.1. Anti-Emetics
    • 8.3.2. Growth Factors
  • 8.4. Targeted Therapy
    • 8.4.1. Monoclonal Antibodies
    • 8.4.2. Tyrosine Kinase Inhibitors

9. Brain Cancer Drugs Market, by Route Of Administration

  • 9.1. Intrathecal
  • 9.2. Intravenous
  • 9.3. Oral

10. Brain Cancer Drugs Market, by Treatment Modality

  • 10.1. Monotherapy
  • 10.2. Combination Therapy

11. Brain Cancer Drugs Market, by Drug Type

  • 11.1. Branded
  • 11.2. Generic

12. Brain Cancer Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Home Healthcare
  • 12.3. Hospitals

13. Brain Cancer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Brain Cancer Drugs Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Brain Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Brain Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc.
  • 18.2. Amgen Inc.
  • 18.3. Amneal Pharmaceuticals, Inc.
  • 18.4. Arbor Pharmaceuticals, LLC
  • 18.5. AstraZeneca PLC
  • 18.6. Bayer AG
  • 18.7. Bristol-Myers Squibb Company
  • 18.8. Chimerix, Inc.
  • 18.9. Day One Biopharmaceuticals, Inc.
  • 18.10. DNAtrix, Inc.
  • 18.11. Eisai Co., Ltd.
  • 18.12. Eli Lilly and Company
  • 18.13. Emcure Pharmaceuticals Limited
  • 18.14. F. Hoffmann-La Roche Ltd
  • 18.15. GlaxoSmithKline plc
  • 18.16. Ipsen SA
  • 18.17. Johnson & Johnson
  • 18.18. Karyopharm Therapeutics Inc.
  • 18.19. Kazia Therapeutics Limited
  • 18.20. Merck & Co., Inc.
  • 18.21. Merck KGaA
  • 18.22. NextSource Pharmaceuticals, LLC
  • 18.23. Novartis AG
  • 18.24. Novocure GmbH
  • 18.25. Pfizer Inc.
  • 18.26. Servier Pharmaceuticals LLC
  • 18.27. Sumitomo Pharma Co., Ltd.
  • 18.28. Sun Pharmaceutical Industries Limited
  • 18.29. Takeda Pharmaceutical Company Limited
  • 18.30. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN CANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BRAIN CANCER DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BRAIN CANCER DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BRAIN CANCER DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GLIOBLASTOMA MULTIFORME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLIOBLASTOMA MULTIFORME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLIOBLASTOMA MULTIFORME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MENINGIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MENINGIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MENINGIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL METASTATIC BRAIN TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL METASTATIC BRAIN TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL METASTATIC BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PITUITARY TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PITUITARY TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PITUITARY TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMETABOLITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMETABOLITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMETABOLITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLANT ALKALOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PLANT ALKALOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PLANT ALKALOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CAR-T THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CAR-T THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CAR-T THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SUPPORTIVE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUPPORTIVE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUPPORTIVE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-EMETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-EMETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-EMETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GROWTH FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GROWTH FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRATHECAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INTRATHECAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRATHECAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. GCC BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. GCC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. GCC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. GCC BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. GCC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. G7 BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. G7 BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. G7 BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 233. G7 BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. G7 BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. NATO BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. NATO BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. NATO BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. NATO BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. NATO BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. NATO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 282. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 313. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 314. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 315. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 318. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 325. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 326. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 327. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 328. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 329. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 330. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 333. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 335. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 336. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 337. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 338. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 339. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 340. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 341. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 342. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 344. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 345. ITALY BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 346. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 347. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 348. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 349. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 350. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 351. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 352. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 353. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 354. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 355. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 356. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 357. SPAIN BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 358. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 359. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 360. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 361. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 362. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 363. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 364. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 365. SPAIN BRAIN CANCER DRUGS